TABLE 1.
Coagulation factors in patients with COVID‐19 disease and ARDS
| Reference range | Value median (IQR) | |
|---|---|---|
| PT (s) | 10‐12 | 11.4 (10.8‐11.4) |
| APTT (s) | 25‐37 | 34 (31‐42) |
| Platelets (109/L) | 150‐400 | 238 (205‐278) |
| Fibrinogen (g/L) | 1.5‐4.0 | 4.96 (3.94‐8.02) |
| Antithrombin activity (IU/mL) | 0.66‐1.24 | 0.88 (0.80‐1.10) |
| Protein C (IU/mL) | 0.65‐1.35 | 0.84 (0.68‐1.41) |
| Protein S (IU/mL) | 0.70‐1.40 | 0.86 (0.55‐1.00) |
| ADAMTS13 (%) | 60‐146 | 73 (65‐89) |
| VWF activity (IU/mL) | 0.5‐1.87 | 2.9 (1.8‐4.8)* |
| VWF antigen (IU/mL) | 0.5‐1.6 | 3.3 (1.9‐4.9)* |
| VWF Ag/ADAMTS13 ratio | 0.34‐2.7 | 4.0 (2.8‐5.7)* |
| Factor VIII (IU/mL) | 0.5‐2.0 | 3.9 (2.0‐4.9)* |
| D‐ dimer (ug/L FEU) | 0‐550 | 1700 (690‐10330)* |
| LDH (U/L) | 90‐235 | 466 (399‐607)* |
A summary of coagulation parameters from patients with severe COVID19 in intensive care, including those intubated and ventilated and noninvasive ventilation.
Abbreviations: ADAMTS13, a disintegrin‐like and metalloprotease with thrombospondin type 1 motif 13; APTT, activated partial thromboplastin time; LDH, lactate dehydrogenase; PT, prothrombin time; VWF, von willerbrand factor.
*
Elevated above normal range.